KP-CoT-23 (CCDC83) is a novel immunogenic cancer/testis antigen in colon cancer

Song,Myung-Ha; Ha,Jin-Mok; Shin,Dong-Hoon; Lee,Chang‑Hun; Old,Lloyd; Lee,Sang-Yull

doi:10.3892/ijo.2012.1601

KP-CoT-23 (CCDC83) is a novel immunogenic cancer/testis antigen in colon cancer

Authors:
- Myung-Ha Song
- Jin-Mok Ha
- Dong-Hoon Shin
- Chang‑Hun Lee
- Lloyd Old
- Sang-Yull Lee
View Affiliations

Affiliations: Department of Biochemistry, School of Medicine, Pusan National University, Yangsan‑si, Gyeongsangnam‑do 626-770, Republic of Korea, Department of Pathology, School of Medicine, Pusan National University, Yangsan‑si, Gyeongsangnam‑do 626-770, Republic of Korea, Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Published online on: August 22, 2012 https://doi.org/10.3892/ijo.2012.1601
Pages: 1820-1826

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer/testis (CT) antigens are considered target molecules for cancer immunotherapy. To identify novel CT antigens, immunoscreening of a testicular cDNA library was performed using serum obtained from a colon cancer patient who was immunized with a new dendritic cell vaccine. We isolated 64 positive cDNA clones comprised of 40 different genes, designated KP-CoT-1 through KP-CoT-40. Three of these putative antigens, including KP-CoT-23 (CCDC83), had testis-specific expression profiles in the Unigene database. RT-PCR analysis showed that the expression of 2 KP-Cot-23 variants was restricted to the testis in normal adult tissues. In addition, KP-CoT-23 variants were frequently expressed in a variety of tumors and cancer cell lines, including colon cancer. A serological western blot assay showed IgG antibodies to the KP-CoT-23 protein in 26 of 37 colon cancer patients and in 4 of 21 healthy patients. These data suggest that KP-CoT-23 is a novel CT antigen that may be useful for the diagnosis and immunotherapy of cancer.

View Figures

View References

1.	Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
2.	Caballero OL and Chen YT: Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 100:2014–2021. 2009. View Article : Google Scholar : PubMed/NCBI
3.	Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old J: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Kim YD, Park HR, Song MH, Shin DH, Lee CH, Lee MK and Lee SY: Pattern of cancer/testis antigen expression in lung cancer patients. Int J Mol Med. 29:656–662. 2012.PubMed/NCBI
5.	Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F and Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 179:921–930. 1994. View Article : Google Scholar : PubMed/NCBI
6.	van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643–1647. 1991.
7.	Pascolo S, Schirle M, Guckel B, Dumrese T, Stumm S, Kayser S, Moris A, Wallwiener D, Rammensee HG and Stevanovic S: A MAGE-A1 HLA-A A^*0201 epitope identified by mass spectrometry. Cancer Res. 61:4072–4077. 2001.
8.	Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I and Pfreundschuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 92:11810–11813. 1995. View Article : Google Scholar : PubMed/NCBI
9.	de Wit NJ, Weidle UH, Ruiter DJ and van Muijen GN: Expression profiling of MMA-1a and splice variant MMA-1b: new cancer/ testis antigens identified in human melanoma. Int J Cancer. 98:547–553. 2002.PubMed/NCBI
10.	Chen YT, Scanlan MJ, Venditti CA, Chua R, Theiler G, Stevenson BJ, Iseli C, Gure AO, Vasicek T, Strausberg RL, et al: Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc Natl Acad Sci USA. 102:7940–7945. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Scanlan MJ, Altorki NK, Gure AO, Williamson B, Jungbluth A, Chen YT and Old LJ: Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett. 150:155–164. 2000. View Article : Google Scholar : PubMed/NCBI
12.	Chen YT, Venditti CA, Theiler G, Stevenson BJ, Iseli C, Gure AO, Jongeneel CV, Old LJ and Simpson AJ: Identification of CT46/ HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein. Cancer Immun. 5:92005.PubMed/NCBI
13.	Brinkmann U, Vasmatzis G, Lee B and Pastan I: Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res. 59:1445–1448. 1999.PubMed/NCBI
14.	Sato S, Noguchi Y, Ohara N, Uenaka A, Shimono M, Nakagawa K, Koizumi F, Ishida T, Yoshino T, Shiratori Y and Nakayama E: Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors. Cancer Immun. 7:52007.PubMed/NCBI
15.	Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, Chen YT, Old LJ and Scanlan MJ: Immunomic analysis of human sarcoma. Proc Natl Acad Sci USA. 100:2651–2656. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Chen YT, Gure AO, Tsang S, Stockert E, Jager E, Knuth A and Old LJ: Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA. 95:6919–6923. 1998. View Article : Google Scholar : PubMed/NCBI
17.	Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M and Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 94:1914–1918. 1997. View Article : Google Scholar : PubMed/NCBI
18.	Tureci O, Sahin U, Schobert I, Koslowski M, Scmitt H, Schild HJ, Stenner F, Seitz G, Rammensee HG and Pfreundschuh M: The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. 56:4766–4772. 1996.PubMed/NCBI
19.	Tureci O, Sahin U, Zwick C, Koslowski M, Seitz G and Pfreundschuh M: Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci USA. 95:5211–5216. 1998. View Article : Google Scholar : PubMed/NCBI
20.	Lee SY, Williamson B, Caballero OL, Chen YT, Scanlan MJ, Ritter G, Jongeneel CV, Simpson AJ and Old LJ: Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer. Cancer Immun. 4:132004.PubMed/NCBI
21.	Park S, Lim Y, Lee D, Cho B, Bang YJ, Sung S, Kim HY, Kim DK, Lee YS, Song Y and Jeoung DI: Identification and characterization of a novel cancer/testis antigen gene CAGE-1. Biochim Biophys Acta. 1625:173–182. 2003. View Article : Google Scholar : PubMed/NCBI
22.	Song MH, Ha JC, Lee SM, Park YM and Lee SY: Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX. Biochem Biophys Res Commun. 408:195–201. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Cho B, Lim Y, Lee DY, Park SY, Lee H, Kim WH, Yang H, Bang YJ and Jeoung DI: Identification and characterization of a novel cancer/testis antigen gene CAGE. Biochem Biophys Res Commun. 292:715–726. 2002. View Article : Google Scholar : PubMed/NCBI
24.	Domae S, Nakamura Y, Uenaka A, Wada H, Nakata M, Oka M, Kishimoto K, Tsukamoto G, Yoshihama Y, Matsuoka J, et al: Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity. Int J Cancer. 124:2347–2352. 2009. View Article : Google Scholar : PubMed/NCBI
25.	Kim Y and Jeoung D: Role of CAGE, a novel cancer/testis antigen, in various cellular processes, including tumorigenesis, cytolytic T lymphocyte induction, and cell motility. J Microbiol Biotechnol. 18:600–610. 2008.PubMed/NCBI
26.	Iwata T, Fujita T, Hirao N, Matsuzaki Y, Okada T, Mochimaru H, Susumu N, Matsumoto E, Sugano K, Yamashita N, et al: Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability-positive endometrial cancer. Clin Cancer Res. 11:3949–3957. 2005. View Article : Google Scholar : PubMed/NCBI
27.	Kim Y, Park H, Park D, Lee YS, Choe J, Hahn JH, Lee H, Kim YM and Jeoung D: Cancer/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anti-cancer drugs. J Biol Chem. 285:25957–25968. 2010. View Article : Google Scholar : PubMed/NCBI
28.	Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N and Old LJ: Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer. 92:856–860. 2001. View Article : Google Scholar : PubMed/NCBI
29.	Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, et al: Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res. 13:6386–6395. 2007. View Article : Google Scholar : PubMed/NCBI
30.	Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V and Boon T: A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA. 98:10290–10295. 2001. View Article : Google Scholar
31.	Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jager D, et al: Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA. 97:4760–4765. 2000. View Article : Google Scholar : PubMed/NCBI